Market Overview

Revance Doses First Patient in ASPEN Phase 3 Clinical Program of RT002 Injectable for the Treatment of Cervical Dystonia


- RT002 Injectable has potential to be first long-acting neuromodulator
for treatment of a debilitating involuntary muscle movement disorder -

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing neuromodulators for use in treating aesthetic and therapeutic
conditions, today announced initiation of patient dosing in the
company's ASPEN Phase 3 clinical program for its investigational drug
candidate DaxibotulinumtoxinA for Injection (RT002) for the treatment of
cervical dystonia (CD), a movement disorder of the neck.

"In our Phase 2 study, treatment with RT002 resulted in patients
realizing clinically meaningful relief from the pain and disability
associated with cervical dystonia for at least 24 weeks," said Roman
Rubio, MD, Senior Vice President of Clinical Development at Revance.
"Current botulinum toxin injections for cervical dystonia are
administered at approximately 12-week intervals. With the potential for
twice yearly administration, RT002 could represent a meaningful
advancement in treatment, providing significantly prolonged improvement
of symptoms in patients."

"The initiation of our pivotal program is an important milestone for
Revance as we advance our novel long-lasting neuromodulator RT002 in
this important therapeutic indication," said Dan Browne, President and
Chief Executive Officer at Revance. "The FDA granted Orphan Drug
Designation for the use of RT002 in the treatment of cervical dystonia,
and we believe that RT002 can deliver improved patient outcomes not only
in cervical dystonia therapy, but in a number of other muscle movement
disorders as well."

Positive results from the company's open-label, dose-escalating Phase 2
clinical study of RT002 injectable in the treatment of cervical dystonia
were recently published in Movement Disorders Clinical Practice.
The trial demonstrated a median duration of effect of at least 24 weeks
for each of the three dose cohorts studied. For reference, current
treatment of cervical dystonia calls for injection of botulinum toxin
approximately every three months (12 weeks), or four times per year.

The Phase 2 trial achieved its primary efficacy endpoint, demonstrating
a clinically significant mean reduction of 38 percent in the Toronto
Western Spasmodic Torticollis Rating Scale (TWSTRS) - Total score from
baseline at Week 4 across all three cohorts. This mean reduction
continued to increase to 50 percent at Week 6, was 42 percent at Week
12, and was maintained at or above 30 percent through Week 24. For
reference, placebo-controlled trials for botulinum toxin type A products
approved to treat cervical dystonia had a reduction in the TWSTRS –
Total score from baseline of 21 percent to 26 percent at Week 4 and 13
percent to 16 percent at Week 12.

Regarding the Phase 2 study's key secondary endpoint – percentage of
responders showing improvement on Clinician Global Impression of Change
(CGIC) – 97 percent of all patients experienced an improvement in
cervical dystonia symptoms at Week 4. In all three cohorts, RT002
injectable appeared to be generally safe and well-tolerated through Week
24. There were no serious adverse events and no dose-dependent increase
in adverse events. The treatment-related adverse events were generally
transient and mild to moderate in severity, with one case of neck pain
reported as severe. The most common adverse events were dysphagia, or
difficulty in swallowing (14 percent), of which all cases were mild in
severity, injection site redness (8 percent), injection site bruising (5
percent), injection site pain (5 percent), muscle tightness (5 percent)
and muscle weakness (5 percent).

The global neuromodulator opportunity for muscle movement disorders in
2017 was estimated to be more than $1 billion. The company plans to
initiate a Phase 2 program in upper limb spasticity, the largest
indication in the muscle movement segment, later this year.

ASPEN Phase 3 Clinical Program in Cervical Dystonia

The company's ASPEN Phase 3 clinical program consists of two trials to
evaluate the safety and efficacy of RT002 injectable for the treatment
of cervical dystonia in adults: 1) a randomized, double-blind,
placebo-controlled, parallel group trial, and 2) an open-label,
long-term safety trial. The program is expected to enroll a total of
approximately 300 patients at multiple sites in the United States,
Canada, and Europe.

Randomized Trial: Patients will be
randomized to either a low dose or high dose of RT002 injectable or
placebo treatment. Post-treatment, patients will be followed for a
maximum of 36 weeks. The primary efficacy endpoint of the trial will be
the change from baseline in the TWSTRS – Total score. Key secondary
endpoints include the duration of treatment effect, the Clinical and
Patient Global Impression of Changes, and adverse events. Further, the
trial features exploratory efficacy assessments, including the Cervical
Dystonia Impact Profile (CDIP)-58, a disease-specific, patient-rated
questionnaire that measures quality of life.

Open-Label Trial: Patients will receive up
to four continuous treatment cycles of RT002 injectable over the 52-week
observation period. Primary endpoints of the trial are safety and
immunogenicity after multiple cycles of treatment with RT002. Key
secondary endpoints are the change from baseline in TWSTRS – Total
score, and the duration of treatment effect, as well as overall
treatment response based on the Clinical and Patient Global Impression
of Change.

Additional information about the ASPEN Phase 3 program, including
patient eligibility criteria, will be posted shortly at

About Cervical Dystonia

According to the Dystonia Medical Research Foundation, cervical dystonia
is a painful condition in which the neck muscles contract involuntarily,
causing abnormal movements and awkward posture of the head and neck. The
movements may be sustained (tonic), jerky (clonic), or a combination.
Cervical dystonia (also referred to as spasmodic torticollis) may be
primary (meaning that it is the only apparent neurological disorder,
with or without a family history) or may be the results of secondary
causes (such as physical trauma) and can cause considerable pain and

Treatments for cervical dystonia include oral medications,
neuromodulator (botulinum toxin) injections, surgery, and complementary
therapies. Neuromodulators blocks the communication between the nerve
and the muscle, relaxing the muscle, which alleviates abnormal
involuntary movements and postures. Current neuromodulator treatments
for cervical dystonia have a duration of effect of approximately three
months. Cervical dystonia can occur at any age, although most
individuals first experience symptoms in middle age. The condition
affects a few hundred thousand adults and children in the United States
alone. Global Industry Analysts, Inc. estimates the global market for
treating muscle movement disorders with botulinum toxins, including
cervical dystonia, was nearly $1.1 billion in 2017.

About Revance Therapeutics, Inc.

Revance Therapeutics is a biotechnology company developing
neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, including muscle movement disorders and pain.
The company's lead drug candidate, DaxibotulinumtoxinA for Injection
(RT002), is currently in development for the treatment of glabellar
lines, cervical dystonia and plantar fasciitis, with plans to initiate
studies in upper limb spasticity and chronic migraine. RT002 has the
potential to be the first long-acting neuromodulator. Revance has
developed a proprietary, stabilizing excipient peptide technology
designed to create novel, differentiated therapies. The company has a
comprehensive pipeline based upon its peptide technology, including
injectable and topical formulations of daxibotulinumtoxinA. More
information on Revance may be found at

"Revance Therapeutics" and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.

Forward-Looking Statements

This press release contains forward-looking statements, including
statements related to Revance Therapeutics' long-term financial outlook
and other financial performance, the process and timing of, and ability
to complete, current and anticipated future clinical development of our
investigational drug product candidates, including but not limited to
initiation and design of clinical studies for current and future
indications, related results and reporting of such results; statements
about our business strategy, timeline and other goals and market for our
anticipated products, plans and prospects; and statements about our
ability to obtain regulatory approval; and potential benefits of our
drug product candidates and our technologies.

Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from our
expectations. These risks and uncertainties include, but are not limited
to: the outcome, cost, and timing of our product development activities
and clinical trials; the uncertain clinical development process,
including the risk that clinical trials may not have an effective design
or generate positive results; our ability to obtain and maintain
regulatory approval of our drug product candidates; our ability to
obtain funding for our operations; our plans to research, develop, and
commercialize our drug product candidates; our ability to achieve market
acceptance of our drug product candidates; unanticipated costs or delays
in research, development, and commercialization efforts; the
applicability of clinical study results to actual outcomes; the size and
growth potential of the markets for our drug product candidates; our
ability to successfully commercialize our drug product candidates and
the timing of commercialization activities; the rate and degree of
market acceptance of our drug product candidates; our ability to develop
sales and marketing capabilities; the accuracy of our estimates
regarding expenses, future revenues, capital requirements and needs for
financing; our ability to continue obtaining and maintaining
intellectual property protection for our drug product candidates; and
other risks. Detailed information regarding factors that may cause
actual results to differ materially from the results expressed or
implied by statements in this press release may be found in Revance's
periodic filings with the Securities and Exchange Commission (the
"SEC"), including factors described in the section entitled "Risk
Factors" of our quarterly report on Form 10-Q filed May 9, 2018. These
forward-looking statements speak only as of the date hereof. Revance
disclaims any obligation to update these forward-looking statements.

View Comments and Join the Discussion!